LENZ Therapeutics, Inc.
- Open
- 5.60
- Day high
- 5.98
- Day low
- 5.57
- Prev close
- 5.68
- Volume
- 251K
- Mkt cap
- $181M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 0.7
- P/S
- 8.6
- Yield
- —
- Per share
- —
LENZ Therapeutics, Inc. (LENZ) is a Healthcare company listed on NASDAQ. The stock is down 81% over the past year.
LENZ Therapeutics, Inc. (LENZ) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 3 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
LENZ earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 11, 2026 | $-1.10 | $-1.32 | -20.0% | $2M | +8.1% |
| Mar 24, 2026 | $-0.91 | $-1.16 | -27.5% | $2M | -48.5% |
| Nov 5, 2025 | $-0.67 | $-0.59 | +11.9% | $13M | +310.0% |
| Jul 30, 2025 | $-0.58 | $-0.53 | +8.6% | $5M | +600.0% |
| Mar 19, 2025 | $-0.42 | $-0.46 | -9.5% | — | — |
| Aug 14, 2024 | $-0.49 | $-0.40 | +18.4% | — | — |
| Feb 27, 2024 | $-0.13 | $-0.40 | -207.7% | — | — |
| Nov 13, 2023 | $-0.25 | $-0.19 | +24.0% | — | — |
LENZ insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 15, 2026 | Thunen Shelley Bdirector | Grant | 22,100 | $6.63 |
| Jun 15, 2026 | Guerard Fredericdirector | Grant | 22,100 | $6.63 |
| Jun 15, 2026 | Scheiner Zacharydirector | Grant | 22,100 | $6.63 |
| Jun 15, 2026 | RA CAPITAL MANAGEMENT, L.P.director, 10 percent owner: | Grant | 22,100 | $6.63 |
| Jun 15, 2026 | MCCOLLUM JAMES Wdirector | Grant | 22,100 | $6.63 |
| Jun 15, 2026 | Drapkin Kimberlee Cdirector | Grant | 22,100 | $6.63 |
| Jun 15, 2026 | George Jeffrey P.director | Grant | 22,100 | $6.63 |
| Mar 30, 2026 | Chevallard Daniel R.officer: Chief Financial Officer | Buy | 7,500 | $8.57 |
| Mar 30, 2026 | Schimmelpennink Evert B.director, officer: President, CEO and Secretary | Buy | 28,089 | $8.95 |
| Mar 30, 2026 | George Jeffrey P.director | Buy | 5,592 | $8.92 |
| Jan 6, 2026 | Chevallard Daniel R.officer: Chief Financial Officer | Grant | 84,200 | $16.00 |
| Jan 6, 2026 | Odrich Marcofficer: Chief Medical Officer | Grant | 84,200 | $16.00 |
| Jan 6, 2026 | Olsson Shawnofficer: Chief Commercial Officer | Grant | 14,000 | — |
| Jan 6, 2026 | Olsson Shawnofficer: Chief Commercial Officer | Grant | 84,200 | $16.00 |
| Jan 6, 2026 | Schimmelpennink Evert B.director, officer: President, CEO and Secretary | Grant | 358,100 | $16.00 |
Source: LENZ SEC Form 4 filings, latest Jun 15, 2026. For informational purposes only — not investment advice.
See the full LENZ insider & 13F page →LENZ Therapeutics, Inc. company profile
Overview
LENZ Therapeutics, Inc. (NASDAQ:LENZ) is a clinical-stage biopharmaceutical company founded to develop innovative treatments for presbyopia, a common age-related vision condition. The company went public in March 2024 and is headquartered in Del Mar, California. LENZ is currently preparing for the potential commercial launch of its lead product candidate LNZ100, which has completed Phase III clinical trials and has a pending New Drug Application (NDA) with the FDA, with a target approval date of August 8, 2025.
Business
LENZ Therapeutics operates in the ophthalmic pharmaceutical sector, specifically focusing on developing treatments for presbyopia, a vision condition that affects the ability to see objects clearly at close range. Presbyopia is a natural part of aging that occurs when the eye's lens loses flexibility, typically beginning around age 40-45. This condition affects approximately 128 million people in the United States alone, creating a substantial market opportunity estimated at over $3 billion. The company's flagship product candidate is LNZ100, an innovative eye drop formulation containing aceclidine as the active ingredient. Unlike existing presbyopia treatments that use pilocarpine (such as VUITY), LNZ100 employs a unique "pupil-selective" mechanism of action. The drug works by selectively constricting the pupil to create a pinhole effect, which increases depth of field and improves near vision without significantly affecting distance vision. This mechanism allows patients to maintain functional vision at all distances while addressing their presbyopia symptoms. In clinical trials, LNZ100 demonstrated impressive efficacy results, with 71% of participants achieving three or more lines of near vision improvement at both 30 minutes and 3 hours after administration. Additionally, 95% of participants achieved at least two lines of improvement, and the treatment showed an excellent safety profile with no treatment-related serious adverse events across more than 30,000 patient treatment days. The company also has LNZ101 in its pipeline, another presbyopia treatment candidate, though LNZ100 remains the primary focus for near-term commercialization. LENZ operates as a single-segment business focused entirely on ophthalmic drug development, with no current revenue from product sales as it remains in the pre-commercial stage.
Competitive moat
LENZ Therapeutics possesses a moderate but potentially strengthening competitive moat built primarily around intellectual property protection and first-mover advantages in the aceclidine-based presbyopia treatment space. The company holds seven granted patents in the United States extending protection through 2039-2044, with an additional ten patents under review that could potentially extend protection further. This intellectual property portfolio, combined with an expected five years of market exclusivity upon FDA approval, provides meaningful barriers to direct competition. The company's unique pupil-selective mechanism of action using aceclidine differentiates LNZ100 from existing pilocarpine-based treatments like VUITY. This differentiation is significant because LNZ100 demonstrated superior efficacy in clinical trials while maintaining an excellent safety profile. Management positions the product as a "category of one" treatment, suggesting limited direct competition at launch. However, the moat faces several potential challenges. The presbyopia treatment market is attracting significant pharmaceutical industry attention, and larger companies with greater resources could develop competing treatments or alternative approaches. Potential disruption could come from next-generation presbyopia treatments, surgical interventions, or innovative lens technologies. Additionally, biosimilar competition could emerge once patent protection expires, though this timeline extends well into the 2040s. The strength of LENZ's moat will ultimately depend on successful commercial execution, continued innovation in the presbyopia space, and the ability to establish strong relationships with eye care professionals and patients. While the current competitive position appears favorable, the company's relatively small size and single-product focus create vulnerability to well-funded competitors entering the market with superior or alternative treatment approaches.
Risks & safety
LENZ Therapeutics presents a strong financial safety profile with substantial cash reserves and minimal debt, though the company faces typical pre-revenue biotech risks. • Cash position and runway: $194.1 million in cash and cash equivalents as of Q1 2025, providing runway to post-launch positive operating cash flow according to management projections • Debt and solvency: Minimal debt with debt-to-equity ratio of 0.006, excellent current ratio of 23.1, indicating very low solvency risk • Cash burn: Quarterly net cash burn of approximately $15-16 million, which is manageable given current cash position • Valuation metrics: Trading at 3.7x price-to-book ratio, though traditional valuation metrics are less meaningful for pre-revenue biotech companies • Regulatory risk: Primary risk factor is FDA approval uncertainty, with PDUFA date of August 8, 2025 representing a key binary event • Commercial execution risk: Success depends on effective launch and market penetration of LNZ100 in a competitive landscape • Single product dependency: Revenue concentration risk as company's success hinges primarily on LNZ100's commercial performance
Recent development
Over the past two years, LENZ Therapeutics has executed a comprehensive strategy to transition from a clinical-stage company to commercial readiness. The company successfully completed its Phase III CLARITY trial for LNZ100, demonstrating strong efficacy with 71% of participants achieving three or more lines of near vision improvement and an excellent safety profile with zero treatment-related serious adverse events. Following the positive clinical results, LENZ submitted its New Drug Application (NDA) to the FDA, which was accepted with a PDUFA target action date of August 8, 2025. The company completed a mid-cycle FDA review in January 2025 with no significant review issues noted, and FDA clinical trial site inspections are currently underway. On the commercial preparation front, LENZ has made significant investments in building its go-to-market capabilities. The company launched an unbranded "EYEAMSELECTIVE" awareness campaign targeting over 30,000 eye care professionals, generating more than 12 million digital impressions. LENZ has hired over 40% of its planned 88-person sales force, with 97% of new team members having prior eye care or pharmaceutical experience. The company has also secured its manufacturing capabilities by initiating production of potential commercial products and establishing a complete supplier network. Intellectual property strengthening has been another focus area, with seven patents granted and additional applications under review. LENZ completed a $30 million PIPE financing with Ridgeback Capital to support its commercial launch preparations, maintaining a strong cash position of nearly $200 million to fund operations through anticipated positive cash flow generation.
LENZ company profile · for informational purposes only — not investment advice.
Track LENZ with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free